EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis

Emina Halilbasic, Elisabeth Tatscher, Elmar Aigner, Lukas Burghart, Ivo Graziadei, Stephanie Hametner-Schreil, Benedikt Silvester Hofer, Harald Hofer, Andreas Maieron, Mattias Mandorfer, Markus Peck-Radosavljevic, Benedikt Schaefer und 7 weitere

Wiener klinische Wochenschrift · 2026-09 · 138 (S13) · 831-858

DOI: 10.1007/s00508-026-02798-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Wiener klinische Wochenschrift, online erschienen am 09.09.2026. Verfasst von Emina Halilbasic und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. emina.halilbasic@meduniwien.a…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary, Gastroenterology. Die Arbeit nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Graz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This consensus document of the Austrian Society of Gastroenterology and Hepatology (ÖGGH) is intended to provide practical guidance for the management of individuals with primary biliary cholangitis (PBC). PBC is a chronic inflammatory, autoimmune-mediated disease of the intrahepatic bile ducts that can lead to fibrosis and ultimately cirrhosis. Middle-aged women are significantly more frequently affected than men. The pathogenesis is currently not fully understood. Based on the presence of disease-specific autoantibodies, it is classified as an autoimmune liver disease, although a combination of genetic predisposition and environmental factors contribute to disease development and progression. The diagnosis of PBC is based on a cholestatic enzyme pattern together with the presence of anti-mitochondrial antibodies (AMA) or PBC-specific anti-nuclear antibodies (sp100, gp210). A liver biopsy is rarely required to establish the diagnosis; exceptions are the suspicion of a PBC autoimmune hepatitis (AIH) variant syndrome or the absence of the abovementioned antibodies. The therapeutic goal is to reduce cholestatic injury thereby preventing disease progression and to reduce symptoms. Approximately 60–70% of patients achieve clinical and biochemical remission with first-line treatment, i.e., ursodeoxycholic acid (UDCA). Recently, the therapeutic paradigm has shifted from achieving certain predefined response criteria to a normalization of alkaline phosphatase (ALP) together with a low-normal bilirubin level, as the latter was linked to improved outcomes in some subgroups. For patients who do not sufficiently respond to UDCA, the newly approved peroxisome proliferator-activated receptor (PPAR) agonists elafibranor and seladelpar, as well as bezafibrate ( off-label use), should be used as a combination treatment with UDCA. In patients with decompensated cirrhosis, liver transplantation has been associated with good long-term outcomes, albeit disease recurrence occurs in up to 50% by 15 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Cirrhosis, BiliaryGastroenterologyHumansUrsodeoxycholic AcidLiver TransplantationAustriaFemaleAutoantibodiesMaleCholagogues and Choleretics

Stichwörter der Autor:innen

ElafibranorLiver transplantationPBCSeladelparUrsodeoxycholic acid

Substanzen

Ursodeoxycholic AcidAutoantibodiesCholagogues and Choleretics

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. emina.halilbasic@meduniwien.ac.at.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. elisabeth.tatscher@medunigraz.at.
  • First Department of Medicine, University Clinic Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Klinik Ottakring, Wiener Gesundheitsverbund, Vienna, Austria.
  • Department of Internal Medicine, Academic Teaching Hospital, Hall, Austria.

Förderung

  • Medical University of Graz

Zitieren

APA

Halilbasic, E., Tatscher, E., Aigner, E., Burghart, L., Graziadei, I., Hametner-Schreil, S., Hofer, B. S., Hofer, H., Maieron, A., Mandorfer, M., Peck-Radosavljevic, M., Schaefer, B., Sieghart, W., Stradner, M., Traussnigg, S., Wagner, M., Zoller, H., Fickert, P., & Trauner, M. (2026). Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis. Wiener klinische Wochenschrift, 138(S13), 831-858. https://doi.org/10.1007/s00508-026-02798-6

Vancouver

Halilbasic E, Tatscher E, Aigner E, Burghart L, Graziadei I, Hametner-Schreil S, et al. Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis. Wiener klinische Wochenschrift. 2026;138(S13):831-858. doi:10.1007/s00508-026-02798-6

BibTeX
@article{Halilbasic2026,
  author = {Halilbasic, Emina and Tatscher, Elisabeth and Aigner, Elmar and Burghart, Lukas and Graziadei, Ivo and Hametner-Schreil, Stephanie and Hofer, Benedikt Silvester and Hofer, Harald and Maieron, Andreas and Mandorfer, Mattias and Peck-Radosavljevic, Markus and Schaefer, Benedikt and Sieghart, Wolfgang and Stradner, Martin and Traussnigg, Stefan and Wagner, Martin and Zoller, Heinz and Fickert, Peter and Trauner, Michael},
  title = {Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis},
  journal = {Wiener klinische Wochenschrift},
  year = {2026},
  volume = {138},
  number = {S13},
  pages = {831--858},
  doi = {10.1007/s00508-026-02798-6}
}
Kostenlos starten →